NCT06840275 - ASCs in Recently Diagnosed Non-ischemic Heart Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2028

Conditions

Non-Ischemic Heart FailureReduced Ejection Fraction Heart Failure

Interventions

DRUG

Allogeneic adipose tissue-derived mesenchymal stem cells

Two intravenous infusions of C2C\_ASC110 1 month apart. The C2C\_ASC110 product contains 110 million cells.

OTHER

Cryostor CS10

Two intravenous infusions of CryoStor CS10 1 month apart.

Trial Locations (1)

Cardiology Stem Cell Centre, Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Denmark, Copenhagen